Vismodegib bulk supplier for pharma manufacturers

Vismodegib 150mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 150mg

Reference Brands: ERIVEDGE (USA/EU)

Vismodegib is an oral small-molecule inhibitor of the Hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor. It is used in the treatment of adults with metastatic or locally advanced basal cell carcinoma that cannot be treated with surgery or radiation. By blocking abnormal cell signaling, Vismodegib helps slow or stop the growth of cancerous cells. Erivedge is taken orally once daily and is among the first targeted therapies developed for advanced skin cancer.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Vismodegib — third party manufacturing & bulk supply

Vismodegib 150mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Vismodegib is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Vismodegib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Vismodegib →

Back to Listing

Frequently Asked Questions

Vismodegib is used to treat adults with metastatic or locally advanced basal cell carcinoma (BCC) that cannot be treated with surgery or radiation. It works by inhibiting the Hedgehog signaling pathway, which is involved in the growth and development of certain cancers, thereby slowing or stopping tumor progression.

Vismodegib is made from Vismodegib, a small-molecule Hedgehog pathway inhibitor that specifically targets and blocks the Smoothened (SMO) receptor involved in cancer cell signaling.

The trade name of Vismodegib is Erivedge.

Vismodegib (Erivedge) is developed and manufactured by Genentech, a member of the Roche Group, and marketed globally under approved regulatory pathways.

The generic name of Vismodegib is Vismodegib.

The brand name of Vismodegib is Erivedge.

Vismodegib is manufactured in the United States and Switzerland by Genentech and Roche under strict GMP-certified facilities for oncology therapeutics.